Prof. Nicolas Girard joined us at ASCO 2024 to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

 

Prof. Girard reviewed data from the following studies:

  • LBA8505 - Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced NSCLC: Primary results, including overall survival, from the global, phase 3, randomised controlled PALOMA-3 trial
  • LBA8612 - Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced NSCLC: Results from the phase 2 PALOMA-2 study
  • LBA8503 - Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ NSCLC: 5-year progression-free survival and safety from the CROWN study
  • LBA8509 - KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic NSCLC harbouring a KRASG12C mutation
  • LBA8593 - Safety and anti-tumour activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase 1/2 study
  • Abstract 8514 - Phase 1a/1b trial of zongertinib (BI 1810631), a HER2-specific TKI, in patients with HER2 aberration-positive solid tumours: Updated Phase 1a data from Beamion LUNG-1, including progression-free survival data

 

Watch the short video update and download the accompanying slides to see the key data from these trials.

 

Clinical Takeaways

EGFR:

  • PALOMA-2: provides evidence for the efficacy and safety of subcutaneous amivantamab + lazertinib and suggests it could be suitable as a first-line option for patients with EGFR-mutant advanced NSCLC
  • PALOMA-3: subcutaneous amivantamab with lazertinib is noninferior to intravenous amivantamab plus lazertinib and has an improved safety profile and greater convenience

 

ALK:

  • CROWN: after 5 years of treatment, the median PFS of patients with advanced ALK-positive NSCLC treated with lorlatinib has yet to be reached, corresponding with the longest PFS ever reported in advanced NSCLC

 

KRAS:

  • KRYSTAL-12: adagrasib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR over docetaxel in patients with previously treated KRASG12C-mutated NSCLC

 

HER2:

  • SOHO-01: in patients with heavily pre-treated HER2-mutant NSCLC, treatment with BAY 2927088 resulted in rapid, substantial and durable responses
  • Beamion LUNG-1: zongertinib was well tolerated and demonstrated promising initial efficacy in pre-treated patients with HER2-mutated NSCLC

Lung cancer data from ASCO 2024: Educational objectives

 

  • Understand the clinical trial data and emerging profile of targeted therapies for the treatment of molecularly driven lung cancer

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Prof. Nicolas Girard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research grants/support from Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen,  Leo Pharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi and Sivan.

Consultative services for Abbvie,  Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen  Hoffmann-La Roche, Janssen, Leo Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer,  Pierre Fabre, Sanofi and Takeda.

Participation on a data safety monitoring board for Hoffmann-La Roche.

Employment of a family member with AstraZeneca.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

Meet the experts

Other programmes of interest

Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024

Conference update

Episode

4

of 4

episode
Oncology 
ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth
  • clock 3 MIN
  • calendar Jun 2024

This educational programme is supported by an Independent Medical Education Grant from Bayer.